Brief: HBM Holdings Announces Positive Topline Results Of Phase III Clinical Trial Of Batoclimab
06/03/2023 06:01
March 6 (Reuters) - Hbm Holdings Ltd 2142.HK :
* POSITIVE TOPLINE RESULTS OF ITS PHASE III CLINICAL TRIAL
OF
BATOCLIMAB FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
* RESULT FROM PHASE III TRIAL MET PRIMARY ENDPOINT AS WELL
AS KEY
SECONDARY ENDPOINTS
Source text for Eikon: ID:nHKSbmmwBY
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study